Vitamin a and regulation of gene expression

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 4, 1998, Pages 341-346

  Nagpal, Sunil ^a   Chandraratna, Roshantha A S ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; RETINOIC ACID RECEPTOR; RETINOID; RETINOL; SACCHAROMYCES CEREVISIAE PROTEIN;

ANIMAL; CELL DIFFERENTIATION; CELL DIVISION; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; REVIEW;

ACETYLTRANSFERASES; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HISTONE ACETYLTRANSFERASES; HUMANS; RECEPTORS, RETINOIC ACID; RETINOIDS; SACCHAROMYCES CEREVISIAE PROTEINS; VITAMIN A;

EID: 0032107115     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199807000-00005     Document Type: Article

References (27)

1. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 1995; 83:859-869.
2. Nagpal S, Chandraratna RAS. Tazarotene and other novel receptor-and function-selective retinoids. Retinoids 1998; 14:2-6.
3. Nagpal S, Chandraratna RAS. Retinoids as anti-cancer agents. Curr Pharmaceut Design 1996; 2:295-316.
4. Nagpal S, Chandraratna RAS. New dermatological agents for the treatment of psoriasis. Annu Rep Med Chem 1997; 32:201-210. A comprehensive review regarding the mechanism of retinoid action in psoriasis.
5. Nagpal S, Cai J, Zheng T, Patel S, Masood R, Lin GY, et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 1997; 17:4159-4168.
6. DiSepio D, Malhotra M, Chandraratna RAS, Nagpal S. Retinoic acid receptor-nuclear factor-interleukin 6 antagonism: a novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker. J Biol Chem 1997 272:25555-25559.
7. Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar M. Retinoic acid blocks adipogenesis by inhibiting C/EBPβ-mediated transcription. Mol Cell Biol 1997; 17:1552-1561. Together with refs [5,6], this manuscript demonstrates the ligand-dependent antagonism of NF-IL6 by RAR.
8. Nagpal S, Friant S, Nakshatri H, Chambon P. RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993; 12:2349-2360.
9. Nagpal S, Saunders M, Kastner P, Durand B, Nakshatri H, Chambon P. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992; 70:1007-1019.
10. Lehmann JM, Jong L, Fanjul A, Cameron JF, Lu XP, Haefner P, et al. Retinoids selective for retinoid X receptor response pathways. Science 1992; 258:1944-1946.
11. Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RAS. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor responsive gene in skin. J Invest Dermatol 1996; 106:269-274.
12. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997; 109:91-95. This study identified an RAR-responsive gene which is induced by the retinoid in vivo and in three-dimensional tissue type cultures (skin rafts) but not in two-dimensional cultures of keratinocytes and dermal fibroblasts.
13. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR, Heyman RA. RXR agonists activate PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 1998; 18:272-276. The authors report that RXR ligand can activate the RXR-PPARα signal transduction pathway in transfected cells as well as in vivo. They also demonstrate that in hypertriglyceridemic db/db mice, RXR and PPARα ligands lower the triglyceride levels, and together these agents exhibit greater efficacy in their triglyceridemia lowering activity. Furthermore, they show that RXR agonists also raise high-density lipoprotein cholesterol levels. These results indicate RXR agonists or their combination with fibrates as novel approaches to treat patients with hypertriglyceridemia and low high-density lipoprotein cholesterol levels.
14. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 1997; 9:222-232. A comprehensive review with 50 references.
15. Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407-410. This paper describes that RXR agonists can function as insulin sensitizers and decrease hyperglycemia, hypertriglyceridemia and hyperinsulinemia in mouse models of type II diabetes. They conclude that the activation of RXR-PPARγ heterodimer with RXR agonists may provide a novel way of treating type II diabetes.
16. Joyeux A, Cavailles V, Blaguer P, Nicolas JC. RIP140 enhances nuclear receptor-dependent transcription in vivo in yeast. Mol Endocrinol 1997; 11:193-202.
17. vom Baur E, Zecehl C, Heery D, Heine M, Gaarnier JM, Vivat V, et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 1996; 15:110-124.
18. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997; 389:194-198.
19. Walfish PG, Yoganathan T, Yang Y-F, Hong H, Butt TR, Stallcup MR. Yeast hormone response element assays detect and characterize GRIP1 coactivator-dependent activation of transcription by thyroid and retinoid nuclear receptors. Proc Natl Acad Sci USA 1997; 94:3697-3702.
20. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996; 384:641-643.
21. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997; 90:569-580. Together with refs [18,20], this manuscript demonstrates that coactivator proteins can function as histone acetyltransferases.
22. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 1998; 279:1922-1925. The first demonstration of the involvement of a coactivator in nuclear receptor signal transduction in vivo.
23. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277:965-968.
24. Yang X-J, Ogryzko VV, Nishikawa J-I, Howard BH, Nakatani Y. A p300/CBP-associated factor competes with the adenoviral oncoprotein E1A. Nature 1996; 382:319-324.
25. He L-Z, Guidez F, Tribioli C, Peruzzi D, Ruthaardt M, Zelent A, Pandolfi PP. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18:126-135.
26. Lin RL, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998; 391:811-814.
27. Grignani F, Matteis SD, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukemia. Nature 1998; 391:815-818. Together with refs [25,26], this manuscript provides a molecular basis for the retinoid unresponsiveness of a subset of APL patients.